| Julie Connick, FNP-C | |
|
900 Cummings Ctr, Suite 107w, Beverly, MA 01915-6198 | |
| (978) 927-1859 | |
| (978) 774-1062 |
| Full Name | Julie Connick |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 16 Years |
| Location | 900 Cummings Ctr, Beverly, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023260320 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | 274231 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northeast Hospital Corporation | Beverly, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northeast Medical Practice Inc | 2365405024 | 188 |
News Archive
Complex heart imaging can increase cancer risks for children throughout their lifetime, according to a new study co-authored by Le Bonheur Cardiologist Jason Johnson, MD, MHS. The study, which appears in the June 9, 2014 issue of the American Heart Association's journal Circulation, is the first in which researchers quantified cumulative radiation doses in pediatric heart patients and predicted lifetime cancer risks based on the types of exposures.
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it has closed on its previously announced licensing and stock purchase agreements with Teva Pharmaceutical Industries Limited, a top 20 pharmaceutical company, for the development of its novel anti-cancer compound, RX-3117. RX-3117 is a small molecule, new chemical entity (NCE), nucleoside compound that has an anti-metabolite mechanism of action, and has therapeutic potential in a broad range of cancers including colon, lung and pancreatic cancer.
Somatic dysfunction, particularly in the lumbar and sacrum/pelvis regions, is common in patients with chronic lower back pain and contributes to poor functioning and general health, results from the OSTEOPATHIC Trial show.
The Clinical Trials Directive, which came into force in May 2004 in order to create a harmonised framework for clinical drug research across Europe, is still hampering such research, according to new findings presented at the European Cancer Conference (ECCO 14).
› Verified 8 days ago
| Entity Name | Northeast Medical Practice Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235147760 PECOS PAC ID: 2365405024 Enrollment ID: O20050111000265 |
News Archive
Complex heart imaging can increase cancer risks for children throughout their lifetime, according to a new study co-authored by Le Bonheur Cardiologist Jason Johnson, MD, MHS. The study, which appears in the June 9, 2014 issue of the American Heart Association's journal Circulation, is the first in which researchers quantified cumulative radiation doses in pediatric heart patients and predicted lifetime cancer risks based on the types of exposures.
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it has closed on its previously announced licensing and stock purchase agreements with Teva Pharmaceutical Industries Limited, a top 20 pharmaceutical company, for the development of its novel anti-cancer compound, RX-3117. RX-3117 is a small molecule, new chemical entity (NCE), nucleoside compound that has an anti-metabolite mechanism of action, and has therapeutic potential in a broad range of cancers including colon, lung and pancreatic cancer.
Somatic dysfunction, particularly in the lumbar and sacrum/pelvis regions, is common in patients with chronic lower back pain and contributes to poor functioning and general health, results from the OSTEOPATHIC Trial show.
The Clinical Trials Directive, which came into force in May 2004 in order to create a harmonised framework for clinical drug research across Europe, is still hampering such research, according to new findings presented at the European Cancer Conference (ECCO 14).
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Julie Connick, FNP-C 900 Cummings Ctr, Suite 107w, Beverly, MA 01915-6198 Ph: (978) 927-1859 | Julie Connick, FNP-C 900 Cummings Ctr, Suite 107w, Beverly, MA 01915-6198 Ph: (978) 927-1859 |
News Archive
Complex heart imaging can increase cancer risks for children throughout their lifetime, according to a new study co-authored by Le Bonheur Cardiologist Jason Johnson, MD, MHS. The study, which appears in the June 9, 2014 issue of the American Heart Association's journal Circulation, is the first in which researchers quantified cumulative radiation doses in pediatric heart patients and predicted lifetime cancer risks based on the types of exposures.
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it has closed on its previously announced licensing and stock purchase agreements with Teva Pharmaceutical Industries Limited, a top 20 pharmaceutical company, for the development of its novel anti-cancer compound, RX-3117. RX-3117 is a small molecule, new chemical entity (NCE), nucleoside compound that has an anti-metabolite mechanism of action, and has therapeutic potential in a broad range of cancers including colon, lung and pancreatic cancer.
Somatic dysfunction, particularly in the lumbar and sacrum/pelvis regions, is common in patients with chronic lower back pain and contributes to poor functioning and general health, results from the OSTEOPATHIC Trial show.
The Clinical Trials Directive, which came into force in May 2004 in order to create a harmonised framework for clinical drug research across Europe, is still hampering such research, according to new findings presented at the European Cancer Conference (ECCO 14).
› Verified 8 days ago
Ms. Linda G Haynes, PNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 85 Herrick St, The Lynch Building, Beverly, MA 01915 Phone: 978-921-2899 Fax: 978-921-2968 | |
Dr. Judith Lorraine Webb, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 62 West St, Beverly, MA 01915 Phone: 339-224-7862 | |
Mrs. Dallas M Walsh, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 100 Cummings Ctr, Suite 126q, Beverly, MA 01915 Phone: 978-524-8181 | |
Ms. Luanne Marie Off, FNP, MSN, MPH, RN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 19 Dodge Street, Minuteclinic, Beverly, MA 01915 Phone: 866-389-2727 | |
Dr. Gina Pallanta, DNP, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 50 Dodge St, Beverly, MA 01915 Phone: 978-922-2171 | |
Anita Marie Ash, ANP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 77 Herrick St Ste 101, Beverly, MA 01915 Phone: 978-927-4110 |